Vertex Pharmaceuticals Incorporated

Published : April 08th, 2015

Stock Market News for April 08, 2015 - Market News

( 0 vote, 0/5 ) Print article
  Article Comments Comment this article Rating Follow Company  
0
Send
0
comment

Stock Market News for April 08, 2015 - Market News


For a look at the issues currently facing the markets, make sure to read today’s Ahead of Wall Street article

 

The Dow Jones Industrial Average (DJI) declined a meager 0.03%, to close at 17,875.42. The Standard & Poor’s 500 (S&P 500) decreased 0.2% to 2,076.33. The tech-laden Nasdaq Composite Index closed at 4,910.23; losing 0.1%. The fear-gauge CBOE Volatility Index (VIX) went up 0.3% to settle at 14.78. A total of about 3 billion shares were traded on NYSE on Tuesday. Decliners outpaced advancing stocks on the NYSE. For 54% stocks that declined, 43% advanced.

 

The S&P 500 hit an intraday high of 2,089.81, before closing down in negative territory. The Dow also gained as much as 102 points during the day, but lost the gains and closed in the red.

 

Investors were concerned about first quarter earnings results. Stronger U.S. dollar may negatively impact multinationals’ earnings results. Continuous drop in oil prices are also expected to weigh on energy companies. Meanwhile, the day’s trading volume was significantly low as investors restrained from placing big bets ahead of the earnings season. First quarter earnings season will officially kick off with Alcoa (AA) reporting results after the market closes on Wednesday.

 

Investors also remained focused on Tuesday’s jobs data. According to the Labor Department survey, the number of job openings on the last business day of February was 5.133 million, the highest level since Jan 2001. However, the number of people hired to fill jobs as well as those who voluntarily quit declined.

 

Separately, the Board of Governors of the Federal Reserve System reported that consumer credit increased by $15.6 billion in February, following January’s $10.8 billion increase. This increase in the indicator of the potential future spending levels was more than analysts’ expectation of an increase by $14 billion. Consumer credit increased at a seasonally adjusted annual rate of 5.50%. Non-revolving credit increased at an annual rate of 9.50%. However, revolving credit decreased at an annual rate of 5%.

 

Eight out of 10 sectors of the S&P 500 ended in the red. The SPDR S&P Homebuilders ETF (XHB) declined 1.3% and was the biggest loser among the S&P 500 companies. Key holdings including KB Home (KBH), Beazer Homes USA Inc. (BZH), Ryland Group Inc. (RYL), Toll Brothers Inc. (TOL) and The Home Depot, Inc. (HD) decreased 1.8%, 1.4%, 1.6%, 2.6% and 0.6%, respectively.

 

The Utilities Select Sector SPDR (XLU) declined 1.2%, the second highest among the S&P 500 sectors. Key utilities stocks including NextEra Energy Inc (NEE), Exelon Corporation (EXC), Southern Company (SO), PG&E Corporation (PCG) and Duke Energy Corporation (DUK) dropped 1.2%, 0.1%, 1.5%, 1.5% and 0.8%, respectively.

 

Among the gainers were healthcare and energy shares. The Health Care Select Sector SPDR (XLV) advanced 0.2%. Bio-tech stocks contributed to the sector’s upbeat performance. Amgen Inc. (AMGN), Biogen Idec Inc. (BIIB), Vertex Pharmaceuticals Incorporated (VRTX) and Regeneron Pharmaceuticals, Inc. (REGN) increased 1.3%, 1.1%, 1.9% and 0.3%, respectively. Overall, iShares Nasdaq Biotechnology (IBB) gained 0.5%.

 

Energy shares gained as oil prices moved north. Oil prices gained after the U.S. Energy Information Administration forecasted domestic crude oil production will peak in April and May before falling from June to September. WTI crude gained 3.4% to $53.98 per barrel, its highest close since Dec. 30, 2014. Additionally, Brent crude increased 1.7% to $59.10 a barrel, respectively.

 

The Energy Select Sector SPDR (XLE) gained 0.1%. Key energy stocks such as Exxon Mobil Corporation (XOM), Chevron Corporation (CVX) and Kinder Morgan, Inc. (KMI) increased 0.7%, 1.5% and 0.1%, respectively.

 

Meanwhile, deal news between FedEx Corporation (FDX) and TNT Express helped limit the day’s losses. FedEx announced that it will acquire one of Europe’s largest delivery companies, TNT Express, for $4.8 billion. In this deal, FedEx will buy each share of the delivery company for $8.75. Shares of FedEx gained 2.7%.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ALCOA INC (AA): Free Stock Analysis Report
 
KB HOME (KBH): Free Stock Analysis Report
 
BEAZER HOMES (BZH): Get Free Report
 
RYLAND GRP INC (RYL): Get Free Report
 
TOLL BROTHERS (TOL): Free Stock Analysis Report
 
HOME DEPOT (HD): Free Stock Analysis Report
 
NEXTERA ENERGY (NEE): Free Stock Analysis Report
 
EXELON CORP (EXC): Free Stock Analysis Report
 
SOUTHERN CO (SO): Free Stock Analysis Report
 
PG&E CORP (PCG): Free Stock Analysis Report
 
DUKE ENERGY CP (DUK): Free Stock Analysis Report
 
AMGEN INC (AMGN): Free Stock Analysis Report
 
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
 
VERTEX PHARM (VRTX): Free Stock Analysis Report
 
REGENERON PHARM (REGN): Free Stock Analysis Report
 
EXXON MOBIL CRP (XOM): Free Stock Analysis Report
 
To read this article on Zacks.com click here.

Read the rest of the article at finance.yahoo.com

CODE :
Follow and Invest
Add to watch list Add to your portfolio Add or edit a note
Add Alert Add to Watchlists Add to Portfolio Add Note
ProfileMarket
Indicators
VALUE :
Projects & res.
Press
releases
Annual
report
RISK :
Asset profile
Contact Cpy

Vertex Pharma is based in United states of america.

Vertex Pharma is listed in United States of America. Its market capitalisation is US$ 100.2 billions as of today (€ 93.4 billions).

Its stock quote reached its lowest recent point on March 12, 2004 at US$ 10.00, and its highest recent level on May 01, 2024 at US$ 402.14.

Vertex Pharma has 249 070 000 shares outstanding.

Your feedback is appreciated, please leave a comment or rate this article.
Rate : Average note :0 (0 vote) View Top rated
 
Corporate news of
1/27/2016Will Vertex Pharmaceuticals’ Valuation Multiple Improve?
1/26/2016Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - t...
1/26/20165:23 pm Vertex Pharma: Health Canada approves PrORKAMBI
1/26/2016Orkambi: Recent Addition to the Vertex Portfolio
1/26/2016Vertex draws upside bet before earnings
1/25/2016Will Higher Expenses Hurt Vertex's (VRTX) 4Q Earnings?
1/25/2016What Are Wall Street’s Estimates for Vertex Pharmaceuticals?
1/25/2016Vertex Pharmaceuticals: What Are Analysts’ Estimates?
1/20/2016Despite Market and Sector Risks, Why Credit Suisse Now Loves...
1/18/2016Nivalis' N91115 Gets Orphan Drug Status for Cystic Fibrosis
1/15/20164 Biotech Stocks Looking Good this Earnings Season
1/15/2016Vertex Pharmaceuticals (VRTX) Jumps: Stock Moves Up 5.8%
1/5/2016Vertex Announces Upcoming Presentation at the J.P. Morgan He...
12/30/2015Vertex Up 3.2% as Healthcare Sector Continued to Lure Invest...
12/23/2015Vertex Drives IBB’s Large-Caps after Losing for Two Days
12/1/2015Do Hedge Funds Love Intercontinental Exchange Inc (ICE)?
11/27/2015The Zacks Analyst Blog Highlights: BioMarin, Amgen, Vertex, ...
11/23/2015Vertex to Present at the Piper Jaffray Healthcare Conference...
11/23/2015Vertex Appoints Michael J. Parini as Executive Vice Presiden...
11/20/2015Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaft...
11/19/2015Vertex Rises on Two EU Approvals for Drug, Leads XLV’s Large...
11/4/2015Vertex to Present at the Credit Suisse Healthcare Conference...
11/2/2015Health-Care Subpoenas: Should We Start to Worry?
11/2/2015Here’s Why These Four Stocks Are Trending Today
11/2/2015IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Inves...
10/31/2015Vertex Pharma receives subpoena from Department of Justice
10/30/2015Law Offices of Howard G. Smith Commences Investigation on Be...
10/30/2015Vertex, Mylan, CVS subpoenaed by federal agencies
10/30/2015SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On...
10/30/2015Nivalis (NVLS): A Surprise in Store this Earnings Season?
10/29/2015Vertex (VRTX) Posts Narrower Q3 Loss, Ups Kalydeco View
10/29/2015Edited Transcript of VRTX earnings conference call or presen...
10/28/2015Vertex Reports Third Quarter 2015 Financial Results
10/28/2015Vertex reports 3Q loss
10/28/20154:07 pm Vertex Pharma beats by $0.14, beats on revs; raises ...
10/27/2015Will Orkambi Help Vertex (VRTX) Post a Lower Loss in Q3?
10/26/2015Vertex and CRISPR Therapeutics Establish Collaboration to Us...
10/26/20158:03 am Vertex Pharma and CRISPR Therapeutics enter strategi...
10/20/2015Oppenheimer Incrementally More Bullish on Gilead, Remains Ca...
10/12/2015Why Energy Stocks Outperformed the Broad Market on October 6
10/9/2015Vertex to Announce Third Quarter 2015 Financial Results on O...
10/8/2015SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Invest...
10/8/2015Vertex's Kalydeco Gets Priority Review for Expanded Use
10/8/2015Vertex Announces Significant Progress in Its Development Eff...
10/7/2015Supplemental New Drug Application for Use of KALYDECO® (ivac...
10/7/2015Supplemental New Drug Application for Use of KALYDECO® (ivac...
10/7/2015Supplemental New Drug Application for Use of KALYDECO® (ivac...
10/7/2015BioMarin Pharmaceutical Takes a Nosedive Last Week
10/1/2015The Zacks Analyst Blog Highlights: Regeneron, Vertex, Gilead...
9/29/2015Regeneron and Mylan End Up in Green for the Week
9/28/2015Why Argus Thinks Now Is the Time to Buy Vertex
9/25/2015IBB Remained Flat Last Week
9/25/2015Vertex Receives CHMP Positive Opinions for ORKAMBI™ (lumacaf...
9/23/2015XBI’s Biotechnology Stocks Rose Week of September 11
9/22/20155 Biotech Stocks Hit Hard by Hillary Clinton's Tweet
9/22/2015Vertex Outperforms XLV on a Year-to-Date Basis
9/21/2015Biotech stocks fall on Clinton vow to fight 'price gouging'
9/18/2015SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Invest...
9/16/2015XLV and XBI Outperform Benchmark Indexes from August 25–31
9/14/2015Amgen And Biogen Lead Short Interest Surge In Biotechs
9/14/2015Vertex Helps Biotechnology Sector Outperform
9/14/2015How Will Vertex Solve Its Falling Revenue Woes?
9/14/2015Vertex Pharma's Orkambi Gives It Huge Potential, Says Barcla...
9/11/2015Vertex and Biogen Outperformd XLV and SPY
9/8/2015Vertex to Present at the Morgan Stanley Healthcare Conferenc...
8/22/2015How Does Vertex Compare to Its Peers?
8/21/2015Vertex Stock Rises after 2Q15 Results Announcement
8/21/2015Will Orkambi Be a Game Changer for Vertex?
8/19/2015Vertex Awards Two Boston Public High School Students the Ver...
8/11/2015What Drove Vertex’s Revenue in 2Q15?
8/11/2015Vertex Reports 2Q15 Revenues of $166.1 Million
8/11/2015What Led Large-Cap Stocks to Outperform Mid and Small Caps?
8/10/2015Key for Investors: How Are Biotech Stocks Trending?
8/10/2015Biotech Stocks Rise Due to a Stable Market: July 31 Week
8/6/2015The Zacks Analyst Blog Highlights: Amgen, Vertex, Regeneron,...
8/4/20153 Potential Huge Takeover Targets in Biotech
7/31/2015Advanced Estimate: US 2Q Gross Domestic Product Expanded by ...
7/30/2015Vertex Posts Wider Y/Y Loss but Raises Kalydeco Outlook - An...
7/30/2015Large-Cap Healthcare Stocks Outperform Small Caps
7/30/2015Edited Transcript of VRTX earnings conference call or presen...
7/29/2015Vertex Reports Second Quarter 2015 Financial Results
7/29/2015Vertex reports 2Q loss
7/28/2015Will Vertex (VRTX) Surprise with a Lower Loss in Q2? - Analy...
7/28/2015CRBP: Warrant Exercise To Provide Sufficient Cash Through 20...
7/24/2015What to Watch in the Week Ahead and on Monday, July 27
7/21/2015How High? The Backlash Over Rising Prescription Drug Prices ...
7/14/2015Vertex to Announce Second Quarter 2015 Financial Results on ...
7/6/2015Vertex Pharma Is 'Hyped,' H.C. Wainwright Sees 35% Downside
7/5/2015Evercore ISI Analyst Gives Highlights From Vertex's Orkambi ...
7/5/20151:46 pm Vertex Pharma confirms FDA approval of its ORKAMBI t...
7/2/2015Business Highlights
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015FDA clears drug for leading form of cystic fibrosis
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015Vertex Pharma's lung disorder therapy wins FDA nod
7/2/2015Vertex Shares Leap On FDA Approval For Cystic Fibrosis Combo...
7/2/2015FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Med...
6/18/2015Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Direc...
6/12/2015Edited Transcript of VRTX presentation 11-Jun-15 4:20pm GMT
5/8/2015FDA questions benefit of cystic fibrosis drug from Vertex
4/23/2015Why Vertex Pharmaceuticals (VRTX) Stock Might be a Great Pic...
4/21/2015Gilead's Stock Spikes on Possibility of Vertex Deal
4/21/2015Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC C...
4/21/2015Bernstein: It's Time For Gilead To Pull The Trigger On This ...
4/17/2015Biotech Investors Shouldn't Miss These Stocks This Earnings ...
4/15/2015Will a New Vertex Drug for Cystic Fibrosis Become a Budget B...
4/9/2015Vertex to Announce First Quarter 2015 Financial Results on A...
4/8/2015Stock Market News for April 08, 2015 - Market News
3/26/2015The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex,...
3/26/2015One analyst is convinced the biotech stock plunge is 'misgui...
3/24/2015Vertex Falls on Disappointing Kalydeco+VX-661 Combo Data - A...
3/24/2015Vertex Treatment May Have High Risk of Failure, Analyst Sugg...
3/24/2015Stock Market News for March 24, 2015 - Market News
3/23/2015Deutsche Bank: Vertex Pharma's Disappointing VX-661 Trial Re...
3/23/2015Vertex Falls Below Buy Point On Cystic-Fibrosis Drug Data
3/23/2015Pfizer and ImmunoGen are big market movers
3/23/2015ICYMI: Pharmaceutical Stocks Are Moving Big On Monday
Comments closed
 
Latest comment posted for this article
Be the first to comment
Add your comment
NASDAQ (VRTX)
402.14+2.38%
US$ 402.14
05/01 17:00 9.33
2.38%
Prev close Open
392.81 392.81
Low High
392.47 406.90
Year l/h YTD var.
392.81 -  446.08 -2.13%
52 week l/h 52 week var.
323.57 -  446.08 16.22%
Volume 1 month var.
1,163,388 -1.78%
Produces
Develops
Explores for
 
 
 
Analyse
Interactive chart Add to compare
Interactive
chart
Print Compare Export
You must be logged in to use the porfolio and watchlists (free)
Top Newsreleases
MOST READ
Annual variation
DateVariationHighLow
202414.24%
202321.89%367.00282.41
202230.17%324.75219.10
2021-6.14%238.26176.36
20206.96%306.08197.47
 
5 years chart
 
3 months chart
 
3 months volume chart
 
 
Mining Company News
Plymouth Minerals LTDPLH.AX
Plymouth Minerals Intersects Further High Grade Potash in Drilling at Banio Potash Project - Plannin
AU$ 0.12-8.00%Trend Power :
Santos(Ngas-Oil)STO.AX
announces expected non-cash impairment
AU$ 7.44-1.26%Trend Power :
OceanaGold(Au)OGC.AX
RELEASES NEW TECHNICAL REPORT FOR THE HAILE GOLD MINE
AU$ 2.20+0.00%Trend Power :
Western Areas NL(Au-Ni-Pl)WSA.AX
Advance Notice - Full Year Results Conference Call
AU$ 3.86+0.00%Trend Power :
Canadian Zinc(Ag-Au-Cu)CZN.TO
Reports Financial Results for Q2 and Provides Project Updates
CA$ 0.12+4.55%Trend Power :
Stornoway Diamond(Gems-Au-Ur)SWY.TO
Second Quarter Results
CA$ 0.02+100.00%Trend Power :
McEwen Mining(Cu-Le-Zn)MUX
TO ACQUIRE BLACK FOX FROM PRIMERO=C2=A0
US$ 11.55+0.79%Trend Power :
Rentech(Coal-Ngas)RTK
Rentech Announces Results for Second Quarter 2017
US$ 0.20-12.28%Trend Power :
KEFIKEFI.L
Reduced Funding Requirement
GBX 0.53-1.12%Trend Power :
Lupaka Gold Corp.LPK.V
Lupaka Gold Receives First Tranche Under Amended Invicta Financing Agreement
CA$ 0.06+0.00%Trend Power :
Imperial(Ag-Au-Cu)III.TO
Closes Bridge Loan Financing
CA$ 2.63-0.75%Trend Power :
Guyana Goldfields(Cu-Zn-Pa)GUY.TO
Reports Second Quarter 2017 Results and Maintains Production Guidance
CA$ 1.84+0.00%Trend Power :
Lundin Mining(Ag-Au-Cu)LUN.TO
d Share Capital and Voting Rights for Lundin Mining
CA$ 15.35-2.35%Trend Power :
Canarc Res.(Au)CCM.TO
Canarc Reports High Grade Gold in Surface Rock Samples at Fondaway Canyon, Nevada
CA$ 0.26+4.08%Trend Power :
Havilah(Cu-Le-Zn)HAV.AX
Q A April 2017 Quarterly Report
AU$ 0.22-6.52%Trend Power :
Uranium Res.(Ur)URRE
Commences Lithium Exploration Drilling at the Columbus Basin Project
US$ 6.80-2.86%Trend Power :
Platinum Group Metals(Au-Cu-Gems)PTM.TO
Platinum Group Metals Ltd. Operational and Strategic Process ...
CA$ 1.83+5.17%Trend Power :
Devon Energy(Ngas-Oil)DVN
Announces $340 Million of Non-Core Asset Sales
US$ 50.42-1.48%Trend Power :
Precision Drilling(Oil)PD-UN.TO
Announces 2017Second Quarter Financial Results
CA$ 8.66-0.35%Trend Power :
Terramin(Ag-Au-Cu)TZN.AX
2nd Quarter Report
AU$ 0.04+0.00%Trend Power :